January 27 (SeeNews) - Slovenian pharmaceuticals producer Krka [LJE:KRKG] said that its net profit rose by an estimated 17% last year, reaching 361.1 million euro ($392.7 million).
Consolidated revenue is seen at 1.717 billion euro in 2022, up 10% year-on-year, while earnings before interest, tax, depreciation and amortisation (EBITDA) are estimated at 488.2 million euro, up 5%, Krka said in a filing to the Ljubljana Stock Exchange on Thursday, citing a preliminary unaudited assessment of financial results.
"Investments at group level amounted to 106 million euro and are expected to increase further this year," Krka noted, without providing figures.
In 2022, Krka obtained marketing authorisations for nine prescription pharmaceuticals and two non-prescription products, and completed 490 marketing authorisation procedures, it said.
"The business operations of the Krka Group in 2022 were successful. Our sound business model and constant adjustments in various areas of operation helped us tackle the challenges we were faced with last year. The recorded revenue was the strongest since incorporation," CEO Joze Colaric said in the statement.
The company's shares closed 1.86% higher at 98.80 euro on Thursday on the Ljubljana bourse.
($ = 0.91943 euro)
KRKA d.d. is among the biggest companies in SEE, for more reference take a look at
Top 100 companies